

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Sep 2026

Overactive bladder(OAB) treatment by Intravaginal injection of botulinum toxin A (Dysport): An effective outpatient procedure

Protocol summary

Study aim

Evaluation of the effect of intravaginal injection of Dysport on reducing the symptoms of overactive bladder, as a less invasive method compared to the conventional intravesical injection evaluation the effect of intravaginal injection on reducing pain in patients with overactive bladder suffering from simultaneous chronic pelvic pain syndrome

Design

Two arm parallel groups clinical trial on 50 patients

Settings and conduct

Adult women with overactive bladder who referred to the urology clinic of Labbafinejad Hospital. First group: after receiving regional or general anesthesia, the appropriate dose of Dysport (10 U/kg) is diluted by normal saline (1 cc/100 units). The solution is injected into the detrusor at 20 different points with a special 22 gauge needle through cystoscope, and the Foley catheter is fixed. Second group: local anesthesia is applied on an outpatient basis by lidocaine ,then the standard dose of Dysport is injected in 10 different points of anterior vaginal wall adjacent to the bladder with the fine 31 gauge needle. Foley catheter is not necessary. For all patients, the ICIQ-OAB questionnaire will be completed before and 4 weeks after the intervention. In patients with OAB and CPPS, the VAS-Score questionnaire is completed at the same time intervals.

Participants/Inclusion and exclusion criteria

Inclusion: Adult women with overactive bladder who are candidates for botulinum toxin injection. Exclusion: Under 18 years old, Known cases of neurological defects, Active UTI, Intact hymen

Intervention groups

Control group: receiving Dysport by the standard intravesical method Intervention group: receiving Dysport by the new method of intravaginal injection

Main outcome variables

The rate of OAB symptoms reduction The rate of pain reduction Complications Rate: Hematuria, dysuria,

infection, need for intermittent catheterization

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20211203053261N1**

Registration date: **2022-05-28, 1401/03/07**

Registration timing: **registered_while_recruiting**

Last update: **2022-05-28, 1401/03/07**

Update count: **0**

Registration date

2022-05-28, 1401/03/07

Registrant information

Name

Maede Mohseni

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 81 3838 0704

Email address

mao.mohseni@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-12-22, 1400/10/01

Expected recruitment end date

2022-09-23, 1401/07/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title
Overactive bladder(OAB) treatment by Intravaginal injection of botulinum toxin A (Dysport): An effective outpatient procedure

Public title
Overactive bladder treatment by Intravaginal injection of botulinum toxin A

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Adult women with overactive bladder who have not responded to initial medical treatment
Exclusion criteria:
Age under 18 years patients with neurogenic bladder (known cases of neurological defects) Active UTI Women with intact Hymen

Age
From **18 years** old

Gender
Female

Phase
3

Groups that have been masked
No information

Sample size
Target sample size: **50**

Randomization (investigator's opinion)
Not randomized

Randomization description

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of urology and nephrology research center, Shahid Beheshti university of medical sc
Street address
No 103, Boostan 9, Pasdaran AV, Tehran
City
Tehran
Province
Tehran
Postal code
1666663111

Approval date
2021-10-02, 1400/07/10
Ethics committee reference number
IR.SBMU.UNRC.REC.1400.005

Health conditions studied

1

Description of health condition studied
overactive bladder
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
ICIQ-OAB symptom score
Timepoint
Before and 4 weeks after intervention
Method of measurement
Validated questionnaire

Secondary outcomes

1

Description
Pain severity
Timepoint
Before and 4 weeks after intervention
Method of measurement
VAS score

2

Description
Incidence of gross hematuria
Timepoint
Within a week after the intervention
Method of measurement
View Foley catheter / Ask the patient

3

Description
Incidence of dysuria
Timepoint
Within a week after the intervention
Method of measurement
Ask the patient

4

Description
Incidence of UTI
Timepoint
Within a week after the intervention
Method of measurement
Urine culture

5

Description

Incidence of urinary retention and need for CIC

Timepoint

Within a week after the intervention

Method of measurement

Ultrasonography and ask the patient

Intervention groups

1

Description

Intervention group: Intravaginal Dysport (Abobotulinum toxin A, Ipsen Biop- harmaceuticals, Pharma, Germany) injection: In this group, local anesthesia is applied on an outpatient basis; diluted lidocaine is injected in to the anterior wall of the vagina at the lithotomy position. The standard dose of Dysport (10 units per kilogram of patient's body weight) is then diluted by injectable normal saline (1 cc per 100 units) and injected into 10 points of the anterior vaginal wall, adjacent to the bladder, by an insulin syringe (very fine 31 gauge needle). Foley catheter is not necessary at the end of procedure.

Category

Treatment - Surgery

2

Description

Control group: Intravesical Dysport (Abobotulinum toxin A, Ipsen Biop- harmaceuticals, Pharma, Germany) injection: After regional or general anesthesia, cystoscopy and bladder washing are performed at the lithotomy position . The appropriate dose of Dysport, equivalent to 10 units per kilogram of patient weight (maximum 1000 units), is diluted with injectable normal saline (1 cc per 100 units). The final solution is injected into 20 different points of detrusor muscle by a special 22 gauge bladder injection needle (BoNee ;Coloplast, Humlebaek, Denmark) through cystoscope, and Foley catheter is fixed at the end of the procedure.

Category

Treatment - Surgery

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Labbafinejad medical center

Full name of responsible person

Farzaneh Sharifiaghdas

Street address

Pasdaran

City

Tehran

Province

Tehran

Postal code

1666663111

Phone

+98 21 2256 7222

Fax

+98 21 2256 7282

Email

mao.mohseni@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Farzaneh Sharifiaghdas

Street address

No103, Boostan 9, Pasdaran

City

Tehran

Province

Tehran

Postal code

1666663111

Phone

+98 21 2256 7222

Fax

+98 21 2256 7282

Email

moa.mohseni@gmail.com

Grant name

Urology and Nephrology Research Center

Grant code / Reference number

0

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shahid Beheshti University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Hamedan University of Medical Sciences

Full name of responsible person

Maede Mohseni

Position

Assistant professor

Latest degree
Subspecialist

Other areas of specialty/work
Urology

Street address
Urology and Nephrology Research Center, Shahid Beheshti Hospital, Eram Boulevard, Hamadan,Iran

City
Hamadan

Province
Hamadan

Postal code
6517953371

Phone
+98 81 3838 0704

Email
mao.mohseni@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Hamedan University of Medical Sciences

Full name of responsible person
Maede Mohseni

Position
Assistant Professor

Latest degree
Subspecialist

Other areas of specialty/work
Urology

Street address
Urology and Nephrology Research Center, Shahid Beheshti Hospital, Eram Boulevard, Hamadan,Iran

City
Hamadan

Province
Hamadan

Postal code
6517953371

Phone
+98 81 3838 0704

Email
mao.mohseni@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Hamedan University of Medical Sciences

Full name of responsible person
Maede Mohseni

Position
assistant professor

Latest degree

Subspecialist

Other areas of specialty/work
Urology

Street address
Urology and Nephrology Research Center, Shahid Beheshti Hospital, Eram Boulevard, Hamadan,Iran

City
Hamadan

Province
Hamadan

Postal code
6517953371

Phone
+98 81 3838 0704

Email
mao.mohseni@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

The information will be entered as code in SPSS software and the analysis results will be published as a final report and article

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable

Title and more details about the data/document

According to the proposal, the data will be entered in accordance with the variables in SPSS software

When the data will become available and for how long

All information will be provided to the Research Center after the approval of the final report and preparation of the article

To whom data/document is available

Executors of the project

Under which criteria data/document could be used

If you need to continue the project with a larger sample size after preparing the proposal and approving it

From where data/document is obtainable

Urology and nephrology research center

What processes are involved for a request to access data/document

After the approval of the executor of the project and approval in the research council of the research center

Comments